Zimmer Biomet Holdings, Inc. ZBH will release its Q3 2024 results on October 30, before the market opens.
In the last quarter, ZBH earned $2.01 per share, exceeding estimates by 1.5%. It has beaten earnings estimates for four consecutive quarters, averaging a 2.84% surprise.
Q3 Expectations
Revenue is projected at $1.81 billion, a 3.3% increase from the previous year. Earnings are estimated at $1.75 per share, which is a 6.1% rise year-over-year.
Estimate Changes
In the last month, the earnings estimate decreased by 1.1% to $1.75 per share.
Growth Factors
Zimmer Biomet likely saw growth this quarter, particularly in its Hip segment, thanks to advancements in surgical solutions and a recent acquisition of OrthoGrid Systems, Inc.
The company plans to introduce new robotic systems and has seen positive trends in its Knees business despite some supply challenges.
ZBH Stock Insights
Zimmer Biomet Holdings, Inc. Price-EPS Surprise
Current Stock Predictions
ZBH’s Earnings ESP is -1.65%, and it holds a Zacks Rank of 4 (Sell), indicating lower chances of beating estimates.
Other Notable Stocks
Consider these medical stocks with better earnings prospects:
- Atea Pharmaceuticals AVIR – Earnings ESP: +13.13%, Zacks Rank: 1 (Strong Buy)
- RadNet RDNT – Earnings ESP: +20.00%, Zacks Rank: 2 (Buy)
- TransMedics Group TMDX – Earnings ESP: +26.63%, Zacks Rank: 3 (Hold)
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. All rights reserved.
`
